Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma

Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma

The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.

Inclusion Criteria:

• request for cryopreserved ovarian tissue transplantation;
• premature ovarian failure or irregular mentrual cycles;
• negative test for HIV, HBV, HCV, Treponema pallidum;
• negative PAP test;
• oncological authorization;
• absence of neoplastic contamination in the cryopreserved ovarian tissue;
• Informed consent

Exclusion Criteria:

• neoplastic contamination in cryopreserved ovarian tissue;
• history of endometriosis;
• endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2);
• body mass index (BMI) >30 kg/m2;
• circulating platelet level < 150,000 / mml;
• bacterial infection;
• ongoing use of anticoagulants;
• bleeding diathesis.